A Randomized, Double-Blind, Placebo-Controlled Phase III Study To Evaluate The Efficacy, Safety, And Tolerability Of Remibrutinib In Patients With Generalized Myasthenia Gravis, Followed By An Open-Label Extension Phase
Posted Date: Sep 10, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
The purpose of this study is to evaluate the efficacy, safety and tolerability of remibrutinib in patients with generalized Myasthenia Gravis (gMG) who are acetylcholine receptor positive (AChR+), muscle-specific tyrosine kinase positive (MuSK+), or double-seronegative (AChR- and MuSK-) who are on stable, standard-of-care (SOC) treatment.
Criteria:
Adult Patients With Gmg (18-75 Years). Confirmed Diagnosis Of Mgfa Class Ii-Iv Gmg.
Keywords:
Mg
For More Information:
Kaiya Payne
5135585582
payne2ka@ucmail.uc.edu